代谢相关性脂肪性肝病流行现状

doi:10.3969/j.issn.1672-5069.2023.06.003

Abstract

Shi Yiwen, Fan Jiangao. Epidemiologic status of metabolic dysfunction-associated fatty liver diseases[J]. Journal of Practical Hepatology, 2023, 26(6): 777-780.

[1] 杨蕊旭, 范建高. 非酒精性脂肪性肝病相关肝细胞癌流行病学与筛查. 实用肝脏病杂志,2022,25(2):153-156.
[2] 苏佩华. 慢性乙型肝炎合并非酒精性脂肪性肝病与肝细胞癌. 实用肝脏病杂志, 2023,26(3):445-448.
[3] Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty Liver disease. Gastroenterology, 2020,158(7):1999-2014,e1991.
[4] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020,73(1):202-209.
[5] Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol, 2023[ahead of print].
[6] Yip TC, Fan JG, Wong VW. China’s fatty liver crisis: A looming public health emergency. Gastroenterology, 2023,165(4):825-827.
[7] Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2022,7(9):851-861.
[8] Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology, 2023,77(4):1335-1347.
[9] Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2023,8(1):20-30.
[10] Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol, 2019,71(4):793-801.
[11] Ye Q, Zou BY, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2020,5(8):739-752.
[12] En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut, 2023[ahead of print].
[13] Le MH, Le DM, Baez TC, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol, 2023,79(2):287-295.
[14] Zhou JH, Zhou F, Wang WX, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology, 2020,71(5):1851-1864.
[15] Man S, Deng YH, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: A nationwide study with 5.7 million adults in China. Gastroenterology, 2023,165(4):1025-1040.
[16] 胡灵溪, 安薪宇, 李妹, 等. 超声衰减参数诊断体检人群脂肪肝临床应用价值分析. 实用肝脏病杂志,2023,26(4):488-491.
[17] 范建高, 李小英. NAFLD更名MAFLD、MASLD:背景、异同、对策. 中华肝脏病杂志, 2023,31(8):789-792.
[18] Zeng J, Qin L, Jin Q, et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. Hepatobiliary Pancreat Dis Int, 2022,21(2):154-161.
[19] Song SJ, Lai JC, Wong GL, et al. Can we use old NAFLD data under the new MASLD definition? J Hepatol, 2023[ahead of print].
[20] Perazzo H, Pacheco AG, Griep RH, et al. Changing from NAFLD trough MAFLD to MASLD: similar prevalence and risk factors in a large Brazilian cohort. J Hepatol, 2023[ahead of print].
[21] Zou ZY, Zeng J, Ren TY, et al. The burden and sexual dimorphism with nonalcoholic fatty liver disease in Asian children: A systematic review and meta‐analysis. Liver Int, 2021,42(9):1969-1980.
[22] Xing YF, Fan JG, Wang HJ, et al. Comparison of MAFLD and NAFLD characteristics in children. Children, 2023,10(3):560.
[23] Zeng J, Jin Q, Yang J, et al. Prevalence and incidence of MAFLD and associated anthropometric parameters among prepubertal children of the Shanghai Birth Cohort. Hepatol Int, 2023[ahead of print].
[24] Zeng J, Shen F, Zou ZY, et al. Association of maternal obesity and gestational diabetes mellitus with overweight/obesity and fatty liver risk in offspring. World J Gastroenterol, 2022,28(16):1681-1691.
[25] 顾棨, 芮法娟, 倪文婧, 等. 非酒精性脂肪性肝病的规范化管理. 实用肝脏病杂志, 2023,26(4):457-460.
[26] 张淮, 郑明华. MAFLD高危人群的筛查和分层管理. 实用肝脏病杂志, 2023,26(4):463-466.

Epidemiologic status of metabolic dysfunction-associated fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zeng Jing, Fan Jiangao. Natural history of metabolic dysfunction-associated fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 769-772.
[2]	Ding Xiaojie, Zhang Yongming, Song Haiyan, et al. Prediction of NAFLD in patients with type 2 diabetes mellitus by NLR and PLR: A preliminary study [J]. Journal of Practical Hepatology, 2023, 26(6): 815-818.
[3]	Ning Yueji, Cheng Jifei, Qian Ji, et al. Clinical features of pyogenic liver abscess in patients with underlying type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2023, 26(5): 730-733.
[4]	Yin Huifen, Yu Hongyan, Liu Zhiping. Changes of serum leptin, retinol-binding protein-4 and cholinesterase levels in patients with NAFLD and T2DM [J]. Journal of Practical Hepatology, 2023, 26(4): 500-503.
[5]	Wang Yunyun, Wu Wanfeng, Li Li. Antiviral efficacy and impact on blood glucose control of direct acting antivirals in treatment of patients with genotype 1b chronic hepatitis C and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2023, 26(3): 344-347.
[6]	Zhao Lingling, Wang Beibei, Yao Yongli, et al.. Serum resistin and triacylglycerol glucose index in patients with T2DM and non-alcoholic fatty liver: their combination for progressive fibrosis [J]. Journal of Practical Hepatology, 2023, 26(3): 356-359.
[7]	Zhang Wei, Chen Guolin, Wang Hang, et al.. Clinical feature of patients with pyogenic liver abscess with different underlying diseases [J]. Journal of Practical Hepatology, 2023, 26(3): 424-427.
[8]	Li Xiaomeng, Wu Shaoyu, Wang Yuanyuan. Implication of serum homocystein, fibroblast growth factor-21 and nuclear factor-κB levels in patients with non-alcoholic fatty liver diseases and T2DM [J]. Journal of Practical Hepatology, 2023, 26(2): 202-205.
[9]	Sun Zheng, Wang Xiaoye, Yuan Jing, et al.. Short-term efficacy of dapagliflozin and liraglutide combination in treatment of patients with non-alcoholic fatty liver disease and diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(6): 796-799.
[10]	Cai Yong, Li Jing, Ou Qin. Implications of serum omentin, retinol-binding protein-4 and propeptide of type I procollagen in patients with diabetes mellitus type 2 and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 800-803.
[11]	Sun Ling, Hang Wei, Deng Guozhong. Short-term observation of metformin and pioglitazone combination in treatment of patients with non-alcoholic fatty liver diseases and diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(6): 804-807.
[12]	Wang Yumei, Yuan Xiangdong, Liu Yuling, et al.. Prevalence and clues for non-alcoholic steatohepatitis in obese children/adolescents [J]. Journal of Practical Hepatology, 2022, 25(6): 808-811.
[13]	Zheng Xiyan, Du Fei, Lin Zhiqun, et al.. Metabolic syndrome-related risk factor for disease progression of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(6): 877-880.
[14]	Xi Jiaying, Tang Jiamei, Liu Lingyu, et al.. Evaluation of left ventricular functions by three-dimensional speckle tracking imaging in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2022, 25(5): 661-664.
[15]	Chronic Disease Management Branch, China Pharmaceutical Biotechnology Association. Expert consensus on the management of diabetes mellitus in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 0-S1.